Johnson & Johnson
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
2015 Annual Report
ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver. -
Manufacturers and Wholesalers Street
Nevada AB128 Code of Conduct Compliant Companies Manufacturers and Wholesalers Street City ST Zip 10 Edison Street LLC 13 Edison Street LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Electrophysiology (including Kalila Medical 2- 2016)) Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division (includes Tendyne 9-2015) AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet, Inc. Actavis W.C. Holding, Inc. Morris Corporate Center III, 400 Interpace Parkway Parsippany NJ 07054 Actavis , Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Activis 400 Interpace parkway Parsippany NJ 07054 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Advanced Vision Research, Inc., dba Akorn Consumer Health Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS, Inc. Akorn (New Jersey) Inc. Page 1 of 23 Pages 2/15/2017 Nevada AB128 Code of Conduct Compliant Companies Akorn AG (formerly Excelvision AG) Akorn Animal Health, Inc. -
Towards the Creation of Polymer Composites Which Can Be
TOWARDS THE CREATION OF POLYMER COMPOSITES WHICH CAN BE REFILLED WITH ANTIBIOTICS AFTER IMPLANTATION FOR INFECTION TREATMENT By ERIKA LEAH CYPHERT Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Dissertation Advisor: Horst von Recum, Ph.D. Department of Biomedical Engineering CASE WESTERN RESERVE UNIVERSITY January 2021 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Erika Leah Cyphert Candidate for the Doctor of Philosophy degree*. (signed) Steven Eppell, Ph.D. (chair of committee) Horst von Recum, Ph.D. Eben Alsberg, Ph.D. Agata Exner, Ph.D. Jonathan Pokorski, Ph.D. (date) September 25, 2020 *We also certify that written approval has been obtained for any proprietary material contained therein. 2 To my grandparents with love – Phil and Ann Cyphert Ted and Dorothy Lippold Florence Miller 3 TABLE OF CONTENTS TABLE OF CONTENTS………………………………………………………………..4 LIST OF TABLES…………………………………………………………………..….10 LIST OF FIGURES…………………………………………………………………….13 LIST OF ABBREVIATIONS……………………………………………………….…21 ACKNOWLEDGEMENTS……………………………………………………………24 ABSTRACT…………………………………………………………………………..…27 CHAPTER 1: DIAGNOSIS AND BIOMATERIAL-BASED TREATMENTS FOR PERIPROSTHETIC JOINT INFECTIONS………………………………………….29 1.1. LIMITATIONS OF CLINICAL TREATMENT OF PERIPROSTHETIC INFECTION…………………………………………………………………30 1.1.1. INTRODUCTION…………………………………………….…30 1.1.2. ISOLATION OF MICROBIAL ORGANISMS………………....33 1.1.3. POSSIBLE UNDERLYING PATIENT COMORBIDITIES……33 1.1.4. BIOFILM FORMATION AND BACTERIAL RESISTANCE…34 4 1.1.5. REVISION PROCEDURES/INITIAL TREATMENT FAILURES....................................................................................36 1.1.6. SUMMARY……………………………………………………...37 1.2. NOVEL TREATMENT MODALITIES FOR PJIS………………………...38 1.2.1. LIMITATIONS WITH TRADITIONAL ANTIBIOTIC-LADEN PMMA BONE CEMENT……………………………………..…38 1.2.2. COMMERCIALLY AVAILABLE ALTERNATIVE BIOMATERIALS FOR ANTIBIOTIC-LADEN PMMA BONE CEMENT………………………………………………………...40 1.2.3. -
SEC Form 10-K Annual Report
e10vk 10-K 1 y80744e10vk.htm FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 3, 2010 Commission file number 1-3215 JOHNSON & JOHNSON (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State of incorporation) (I.R.S. Employer Identification No.) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (732) 524-0400 SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT Title of each class Name of each exchange on which registered Common Stock, Par Value $1.00 New York Stock Exchange Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes þ No o Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes o No þ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). -
Management Liability Focus Johnson & Johnson 1
Insured Profile Report – Management Liability Focus Johnson_________________________________________________________________________ & Johnson Company Profile Credit Details Location 1 Johnson and Johnson Plz Overall Credit Risk High Risk New Brunswick, NJ www.jnj.com Number of Legal Derogatory 84 Company Type Public Items Liability Amount $322,285.00 Formerly Known As N/A Experian Intelliscore 2.57 SIC Code 2834 SIC Code Description Pharmaceutical Preparations Experian Intelliscore Percentile 2.00 % of companies score lower and have higher credit risk Established 1955 Experian Commercial IntelliscoreSM is an all-industry commercial model using business information to predict business risk. Its Sales (in millions) $65,030.00 predictiveness is among the best on the market today The objective of the Commercial Intelliscore Model is to predict seriously Employees 117,900 derogatory payment behavior. Possible score range from 0 to 100, where 0 is high risk and 100 is low risk Total OSHA Violations 18 -Liability Amount is the total dollar amount of debtor’s legal liability, OSHA is an arm of the Department of Labor that conducts inspections of company including accounts in collection, tax liens,judgments and/or bankruptcies facilities with the goal of preventing work-related injuries, illnesses and deaths. -The Number of Legal Derogatory items are the sum of Tax-Lien Worksites that do not meet health and/or safety standards at the time of inspection may Count, Bankruptcy,Judgment, Collection-Counter and UCC Derog receive an OSHA violation. Total FDA NDC Drugs 177 The total number of FDA Drugs filed in the FDA NDC Drug Database. Business Description Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. -
Lna 2006 Profiles J.Qxp
1 | Advertising Age | June 26, 2006 SpecialSpecial ReportReport:100 Profiles LEADING NATIONAL ADVERTISERSSupplement SUPPLEMENT June 26, 2006 100 LEADING NATIONAL ADVERTISERS Profiles of the top 100 U.S. marketers in this 51st annual ranking INSIDE TOP 100 RANKING COMPANY PROFILES SPONSORED BY The nation’s leading marketers Lead marketing personnel, ranked by U.S. advertising brands, agencies, agency expenditures for 2005. contacts, as well as advertising Includes data from TNS Media spending by media and brand, Intelligence and Ad Age’s sales, earnings and more for proprietary estimates of the country’s 100 largest unmeasured spending. PAGE 8 advertisers PAGE 10 This document, and information contained therein, is the copyrighted property of Crain Communications Inc. and The Ad Age Group (© Copyright 2006) and is for your personal, non-commercial use only. You may not reproduce, display on a website, distribute, sell or republish this document, or information contained therein, without prior written consent of The Ad Age Group. Are proud to connect you with the leading CMOs See all the interviews at adage.com/point LAUNCHING JUNE 28 © 2006 Crain Communications Inc. www.adage.com 3 | Advertising Age | June 26, 2006 Special Report 100 LEADING NATIONAL ADVERTISERS SUPPLEMENT ABOUT THIS PROFILE EDITION THE 51ST ANNUAL 100 Leading National the Top 100 ($40.13 billion) and for all measured spending in 18 national media, Advertisers Report crowned acquisition- advertisers ($122.79 billion) in the U.S. Yellow Pages Association contributed ladened Procter & Gamble Co. as the top U.S. ad spending by ad category: This spending in Yellow Pages and TNS Marx leader, passing previous kingpen General chart (Page 6) breaks out 18 measured Promotion Intelligence provided free- Motors Corp. -
Annual Report
ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges. -
Bestccoorporations
Navoba BUY VETERAN CORPORATE GOVERNMENT FRANCHISE YOUR BIZ COMMUNITY best corporations HUGE CORPORATE for vETERAN-OWNED By Matthew Pavelek CONTRACTING n 1999, the veteran-owned of their way to use VOBs. business movement took In 2007, approximately 10 a giant leap forward with percent of Fortune 1000 companies legislation requiring the sought veteran-owned suppliers. Ifederal government to recognize Through NaVOBA’s efforts, that vetrepreneurs and setting a mandate number has grown by more than OPPORTUNITIES to buy from businesses owned 60 percent. Today, more than 160 by service-disabled veterans. In Fortune 1000 companies maintain 2005, NaVOBA launched Veterans programs designed to use VOBs as Business Journal to bring the VOB preferred vendors in their supplier movement to corporate America. diversity eff orts. While the federal government is Retail colossus Walmart, FOR the world’s single largest purchaser consumer products behemoth of goods and services, the potential Proctor and Gamble, and innovative for vetrepreneurs selling to all of tech giant Apple, Inc. all buy veteran corporate America dwarfs the federal because it’s good business. Johnson opportunity. & Johnson, earning a place among YOUR BUSINESS Unlike the federal government NaVOBA’s Best 10 Corporations for and its prime contractors, many Veteran-Owned Businesses for 2011 states, and some local and municipal and 2012, provides further evidence governments, corporate America is that the VOB movement is advancing NaVOBA is proud to honor the 10 Best Corporationsporations not mandated by law to use veteran- well beyond the beltway. for Veteran-Owned Businesses for 2012. owned suppliers. Just like any Earning the honor as one of business, large corporations exist to NaVOBA’s 10 Best Corporations for turn a profi t. -
Caring for the World . . .One Person at a Time™ Inspires and Unites the People of Johnson & Johnson
OUR CARING TRANSFORMS 2007 Annual Report Caring for the world . .one person at a time™ inspires and unites the people of Johnson & Johnson. We embrace research and science—bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. The people in our more than 250 companies come to work each day inspired by their personal knowledge that their caring transforms people’s lives . one person at a time. On the following pages, we invite you to see for yourself. Our Caring Transforms ON THE COVER Johnson & Johnson is founding sponsor and continues to support Safe Kids Worldwide®. For 20 years the organization has grown, now teaching prevention as a way to save children’s lives in 17 countries around the world. In Brazil, Nayra Yara da Paz de Jesus carefully washes her hands, a safe, healthy habit she and other children are learning from a local Safe Kids® program. Find out more in our story on page 22. C H A I R M A N ’ S L E T T E R To Our Shareholders Caring for the health and well-being of people throughout the world is an extraordinary business. It is a business where people are passionate about their work, because it matters. It matters to their families, to their communities and to the world. It is a business filled with tremendous opportunity for leadership and growth in the 21st century; a business where unmet needs still abound and where people around the world WILLIAM C. -
The Leading Source of Diabetes Business News It's Complicated
The Leading Source of Diabetes Business News It’s Complicated January/February 2011 • No. 105 The diabetes business used to be fairly straightforward. It’s a lot more complicated now, but that’s not a bad thing. Take insulin. After it was commercialized in the early 1920s, the goal was clear: sell more insulin. But look at today’s three major insulin makers: Eli Lilly, sanofi-aventis, and Novo Nordisk. For all three, to be sure, insulin is still preeminent. The diabetes divisions of Novo Nordisk and Lilly draw most of their revenue from human insulin and rapid-acting analogs, while sanofi-aventis’ blockbuster basal analog Lantus, as well as its mealtime insulins, continue to drive the bottom line. But all three companies have also developed (or are developing) GLP-1 analogs, Lilly has invested in oral drugs for type 2 diabetes (most recently through a major partnership with Boehringer Ingelheim), and the companies are also developing new therapeutic approaches for different stages of disease progression. The evolution of the insulin makers reflects broader industry trends. As our understanding of diabetes has expanded – and we dig deeper into the molecular complexities of the disease – it’s clear that single- focus large companies can no longer prosper. Ours is an era of individualized treatment that mixes and matches different drugs and technologies that try to meet the unique needs of every person with diabetes. Toward that end, companies are forming partnerships to find complementary therapies and development efforts that will create -
FORM 10-Q Johnson & Johnson
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended July 4, 2021 or Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ☐ for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (Address of principal executive offices) Registrant’s telephone number, including area code (732) 524-0400 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☑ Yes ☐ No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☑ Yes ☐ No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. -
• Dell • E. & J. Gallo Winery • Heineken • Johnson
Featuring these providers: • DELL • E. & J. GALLO WINERY • HEINEKEN • JOHNSON & JOHNSON • KIMBERLY-CLARK • MONDELÉZ • NOVARTIS • PEPSICO • PROCTER & GAMBLE • Western union Special supplement – October 2014 Untitled-3 1 9/10/14 3:37 PM THE 2014 GUIDE TO SHOPPER MARKETING TEAMS ADVERTISEMENT www.DELL.com Consumer electronics expertise. Shopper insights. AT-A-GLANCE We’ve leveraged our unique experience as both a manufacturer and a retailer to develop an insights- and experience-based process to systematically and EXPERTISE strategically grow our business—and yours. While Dell is a well-known We work with our retail partners to: manufacturer, we are also a retailer. With 30 years of direct • Identify opportunities for mutual growth and online sales, Dell has rich • Apply our superior shopper and category under- insights about consumer standing to solution development electronics shoppers. Now • Implement solutions that address shopper needs selling in brick-in-mortar stores, Dell has a Shopper Marketing • Test solutions and develop performance metrics team sharing its unique • Consistently apply learnings to strategically grow Dell understands the issues and dynamics that make perspective with partner retailers. the category and our brand shopper marketing in consumer electronics unique, starting with a longer shopping journey. Through Dell’s Shopper Marketing Account Managers support omni-channel selling strategies and continuous their retailers’ personalized shopper marketing KEY EXECUTIVES innovation, we take full advantage of opportunities solutions. Our ongoing consultation and partnership is Lorrie Schultz, Executive Director to influence the consumer. And with our dedicated framed by a formal Shopper Marketing program, but Shopper Marketing team, we aim to be our retailers’ we are also agile and able to assist with ad-hoc needs Dan Seymour, Director, NA #1 shopper marketing partner.